Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04FXS
|
|||
| Former ID |
DNC000557
|
|||
| Drug Name |
Didox
|
|||
| Synonyms |
69839-83-4; N,3,4-Trihydroxybenzamide; 3,4-Dihydroxybenzohydroxamic acid; NSC-324360; Benzamide, N,3,4-trihydroxy-; 3,4-Dihydroxyphenylhydroxamic acid; UNII-L106XFV0RQ; VF 147; NSC 324360; DIDO; CCRIS 7909; BRN 2096682; L106XFV0RQ; C7H7NO4; NSC324360; AC1L1F1T; Benzamide,3,4-trihydroxy-; AC1Q5DI9; N-3,4-Tridhydroxybenzamide; SCHEMBL171446; CHEMBL367788; SCHEMBL18732059; Didox, > SCHEMBL18346609; CTK8F9165; DTXSID90220134; QJMCKEPOKRERLN-UHFFFAOYSA-N; MolPort-009-019-216; KS-00001DF2; BCP16846; ZINC3872288; 1716AH
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Discontinued in Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C7H7NO4
|
|||
| Canonical SMILES |
C1=CC(=C(C=C1C(=O)NO)O)O
|
|||
| InChI |
1S/C7H7NO4/c9-5-2-1-4(3-6(5)10)7(11)8-12/h1-3,9-10,12H,(H,8,11)
|
|||
| InChIKey |
QJMCKEPOKRERLN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 69839-83-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
457824, 634609, 5632198, 8151938, 11407208, 12013951, 15066661, 15171157, 29222191, 49877397, 50731210, 57321575, 71822596, 103433469, 103834548, 104302366, 117562122, 125335454, 127274074, 127274075, 127274076, 127274077, 127274078, 127274079, 127274080, 127274081, 127274082, 127274083, 127274084, 127274085, 127274086, 127274087, 127274088, 127274089, 127274090, 127274091, 127274092, 127274093, 127274094, 127274095, 127274096, 127274097, 127274098, 127274099, 127274100, 127274101, 127274102, 127274103, 127274104, 127274105
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ribonucleotide reductase (RIR) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002464) | |||
| REF 2 | Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3. Cancer Biol Ther. 2002 Sep-Oct;1(5):539-45. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.